New hope for easing debilitating muscle lock in rare disease
NCT ID NCT06523400
Summary
This study is testing whether a daily, extended-release version of the drug mexiletine can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 participants will take either the real drug or a placebo for 26 weeks to see if it helps them relax their grip and move more easily. The main goal is to see if the treatment improves the time it takes for hand muscles to relax after squeezing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
RECRUITINGRome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
RECRUITINGLeuven, Belgium
-
Ludug-Maximilians University
RECRUITINGMünchen, Germany
-
Saint George's University Hospitals NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
-
University College Hospital
RECRUITINGLondon, United Kingdom
-
University Hospital of Madrid
RECRUITINGMadrid, Spain
Conditions
Explore the condition pages connected to this study.